3D-Printed Drug Market Expands on Personalized Medicine Demand
Key Points
- The global 3D-printed drug market was valued at $296.36 million in 2025 and is forecast to reach $520.73 million by 2033, a 7.3% CAGR, according to DataM Intelligence.
- 3D printing allows tailored drug strength, shape, size, porosity and release, including polypills, with North America holding the largest share at 42.4%.
- PharmaTher's M3DICINES and PERSONALIZ3D initiatives and EMA guidance in March 2026 highlight growing personalized manufacturing, while quality and regulatory challenges remain.
The market for pharmaceutical 3D printing is projected to expand as drug developers and healthcare providers explore additive manufacturing to produce customized medications. According to a new report from DataM Intelligence, the global market was valued at $296.36 million in 2025, up from $281.63 million in 2024, and is forecast to reach $520.73 million by 2033. That represents a compound annual growth rate (CAGR) of 7.3% between 2026 and 2033.
The technology offers pharmaceutical manufacturers greater flexibility in designing dosage forms, allowing them to tailor drug strength, shape, size, porosity and release characteristics to individual patient needs. These capabilities are attracting interest as precision medicine advances and demand grows for treatments that accommodate differences in age, disease state and patient response.
3D printing also offers potential advantages for patients managing complex medication schedules. Customized formulations, including combination products that incorporate multiple active ingredients, could help simplify treatment regimens. Pediatric and geriatric populations may be particular beneficiaries, especially patients who have difficulty swallowing conventional tablets or require doses that are not readily available in standard commercial products.
Several additive manufacturing approaches are contributing to the development of more complex pharmaceutical dosage forms. These include fused deposition modeling, binder jetting, selective laser sintering, inkjet printing and semi-solid extrusion.
The methods can be used to produce a range of formulations, including orally disintegrating tablets, polypills and controlled-release products. Ongoing advances in digital formulation design, pharmaceutical materials and automated production are also expanding the potential applications of the technology.
Artificial intelligence is emerging as another area of interest, with the potential to support formulation development and manufacturing optimization. Together, these developments could help make small-batch and patient-specific drug production more practical.
North America accounted for the largest regional share of the market, at 42.4%, according to the report. Its position reflects the region’s established pharmaceutical research infrastructure, investment in personalized medicine and evolving regulatory environment. Adoption of on-demand manufacturing in hospitals, specialty pharmacies and research laboratories could further support regional growth.
Recent industry activity highlights growing interest in pharmaceutical 3D printing, particularly for personalized and specialized treatments. PharmaTher has announced several initiatives in 2026 centered on its M3DICINES and PERSONALIZ3D platforms. In October, the company outlined plans to expand its pipeline of personalized 3D-printed peptide medicines, initially focusing on colon-targeted KPV and BPC-157 formulations. It also submitted applications to the U.S. FDA seeking Orphan Drug and Rare Pediatric Disease designations for a 3D-printed creatine monohydrate formulation intended for guanidinoacetate methyltransferase (GAMT) deficiency.
Earlier in October, PharmaTher introduced its M3DICINES National Network Program, an initiative to establish a network of pharmaceutical 3D-printing facilities spanning pharmacies, hospitals and contract manufacturing organizations. The proposed network is intended to support on-demand production of personalized treatments, including medicines for rare diseases, discontinued products and drug shortages.
The company has also pursued commercial and development partnerships to expand its platform. In October, PharmaTher entered an exclusive North American distribution agreement with Singapore-based Craft Health for its CraftMake pharmaceutical 3D-printing system. The agreement is intended to broaden access to equipment for customized drug production.
Other 2026 developments include the selection of U.S. 503A compounding pharmacy PD Labs as a Center of Excellence for the PERSONALIZ3D platform and a collaboration with Craft Health to evaluate its GMP-ready CraftMake system for personalized peptide formulations. Potential dosage formats under evaluation include chewable and dissolvable tablets, as well as combination products.
As pharmaceutical 3D printing moves toward broader adoption, manufacturers will need to address quality, process control and regulatory requirements associated with decentralized and customized production.
In March 2026, the European Medicines Agency issued updated questions and answers on the implementation of 3D-printing technology for solid oral dosage forms. The document clarifies expectations related to quality management and Good Manufacturing Practice, providing additional direction for companies developing printed medicines.
While technical and regulatory challenges remain, continued progress in materials, printing platforms and manufacturing controls could help expand the role of additive manufacturing in pharmaceutical development and production.
Total Page Views: 1

















